Pivotal Life Sciences
San Francisco, California, United StatesFounded 2017
Pivotal Life Sciences is a global healthcare investment firm that provides capital to innovative companies developing therapeutic products and technologies to address major unmet medical needs. It invests across all stages, from early-stage startups to publicly traded biotechs, and also engages in venture building and public equity investing.
66% of their portfolio is in Biotech & Life Sciences. Deal activity decreased year-over-year (2 deals in the last 12 months vs 4 prior). Average disclosed round size is $92.4M (across 54 rounds with reported amounts).
Portfolio
40
Fund Size
$389M
Top Stage
Series C
Last 12 Mo
2
Team
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
58 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Crystalys Therapeutics Inc | Series B | $130M | Jul 2026 |
 Addition Therapeutics | Unknown | $100M | Dec 2025 |
 Avalyn Pharma, Inc. | Series D | $100M | Jul 2025 |
 Mosanna Therapeutics | Series A | $80M | Jun 2025 |
 Windward Bio | Series A | $200M | Jan 2025 |
| MMosanna | Series A | $80M | Jan 2025 |
 Windward | Series A | $200M | Jan 2025 |
 Evommune | Series C | $115M | Oct 2024 |
 Zenas BioPharma | Series C | $200M | May 2024 |
 Engrail Therapeutics | Series B | $157M | Mar 2024 |
| EEngrail | Series B | $157M | Mar 2024 |
| Zenas BioPharma | Series C | $200M | Jan 2024 |
 Heranova | Seed | $13.5M | Dec 2023 |
| Avalyn Pharma, Inc. | Series C | $175M | Sep 2023 |
| AAvalyn | Series C | $100M | Sep 2023 |
| Evommune | Series B | $50M | Apr 2023 |
| Avalyn Pharma, Inc. | Series C | $175M | Jan 2023 |
| Heranova | Seed | $13.5M | Jan 2023 |
 Plexium | Growth | $102M | Feb 2022 |
 Arkuda Therapeutics | Series B | $64M | Feb 2022 |
 HotSpot Therapeutics | Series C | $100M | Nov 2021 |
| AAblaze Pharmaceuticals | Series A | $75M | Nov 2021 |
 AptiHealth | Series B | $50M | Nov 2021 |
| Evommune | Series A | $83M | Sep 2021 |
 Obsidian Therapeutics | Series B | $115M | Sep 2021 |
Page 1 of 3
Top Co-Investors
SR One13 shared
Vivo Capital13 shared
Norwest Venture Partners11 shared
Wellington Management11 shared
Rock Springs Capital11 shared
Novo Holdings A/S10 shared
RA Capital Management10 shared
Surveyor Capital9 shared
Sofinnova Partners9 shared
Novo Capital9 shared
RiverVest Venture Partners7 shared
OrbiMed7 shared
Longitude Capital7 shared
Nan Fung Life Sciences6 shared
F-Prime Capital6 shared
Eventide Asset Management6 shared
EQT Life Sciences6 shared
Cormorant Asset Management6 shared
Quan Funds6 shared
Last updated: 7 October 2026